Open Nav

Please submit your session questions in advance at


  • Jonathan Javitt, MD, MPH, NeuroRx

NeuroRx is developing NRX-101, an FDA-designated Breakthrough Therapy targeting Suicidal Bipolar Depression. NRX-101 is a fixed dose combination of D-cycloserine and lurasidone, which is believed to raise Glx in the brain, as does ketamine and ECT.

NeuroRx draws upon 30 years of basic science and clinical expertise in the role of N-methyl-D-aspartate (NMDA), a receptor that regulates human thought processes, particularly depression and suicidality, as well as PTSD. The company is privately funded and led by former senior executives of Johnson & Johnson, BMS, Pfizer Inc., Eli Lilly, and Sunovion.

NeuroRx has entered an FDA phase 2b/3 pivotal trial under a Special Protocol Agreement and a Biomarker Letter of Support for treatment of patients with Severe Bipolar Depression and Acute Suicidal Ideation. Phase 2 data demonstrated an 11 point advantage on MADRS depression scale at day 14 vs. lurasidone alone (P=0.03) and a sustained separation through day 42 (P=0.059).

  • Date:Monday, February 11
  • Time:9:30 AM - 9:45 AM
  • Room:Chelsea
  • Location:7th Floor
  • Session Type:Company Presentation
  • Please submit your session questions in advance:

    Click here.

  • Company Presentation - Presentation Type:Privately Funded Company
  • Submission ID:23351
  • Goal for Presentation:Partnering/Investment
  • Company
  • Company HQ City:Wilmington
  • Company HQ State:Delaware
  • Company HQ Country:United States
  • Total Amount Raised to Date, in All Rounds:$25 million
  • Size of Last Investment Round:$10 million
  • CEO/Top Company Official:Jonathan C. Javitt, MD, MPH
  • Year Founded:2015
  • Main Therapeutic Focus:CNS/Neurological
  • Lead Product in Development:NRX-101
  • Development Phase of Primary Product:Phase III
  • Number Of Unlicensed Products (For Which You Are Seeking Partners):2
Jonathan Javitt, MD, MPH